What risks and benefits should be considered when treating patients with CKD?
The risks, benefits, resource use, and costs of RASi therapy should be considered when treating patients with CKD. The risks associated with RASi therapy include hyperkalemia, AKI due to volume depletion, and other events. The benefits of RASi therapy include prevention of CV outcomes and prevention of CKD progression. The costs of generic RASi medication are generally low, but the use of RASi in patients with CKD G1 G4 with A3 requires patient education, repeat lab testing, vigilance, and repeat visits to restart RASi if it has been stopped during a hospitalization.